RT Journal Article
SR Electronic
T1 Antibody response to SARS-CoV-2 infection and BNT162b2 vaccine in Israel
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.07.21259499
DO 10.1101/2021.07.07.21259499
A1 Shapira, Guy
A1 Hamad, Ramzia Abu
A1 Weiner, Chen
A1 Rainy, Nir
A1 Sorek-Abramovich, Reut
A1 Benveniste-Levkovitz, Patricia
A1 Chaim, Adina Bar
A1 Shomron, Noam
YR 2021
UL http://medrxiv.org/content/early/2021/07/08/2021.07.07.21259499.abstract
AB Neutralizing antibodies targeting the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) block viral entry to host cells, preventing disease and further spread of the pathogen. The presence of SARS-CoV-2 antibodies in serum is a reliable indicator of infection, used epidemiologically to estimate the prevalence of infection and clinically as a measurement of an antigen-specific immune response. In this study, we analyzed serum Spike protein-specific IgG antibodies from 26,170 samples, including convalescent individuals who had coronavirus disease 2019 (COVID-19) and recipients of the BNT162b2 vaccine. We find distinct serological patterns in COVID-19 convalescent and vaccinated individuals, correlated with age and gender and the presence symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not supported by any specific grant and required no additional funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of Shamir (Assaf Harofe) Medical Center and followed the tenets of the Declaration of Helsinki (146-21-asf).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data collected for this study is protected under patient confidentiality laws.